Assenagon Asset Management
SCPH

Assenagon Asset Management’s scPharmaceuticals SCPH Stock Holding History

Assenagon Asset Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,430
Closed -$32.7K – 1227
2025
Q1 		$32.7K Buy
+12,430
New +$40.5K ﹤0.01% 1141
2024
Q3 		– Sell
-72,692
Closed -$316K – 1467
2024
Q2 		$316K Buy
72,692
+52,870
+267% +$232K ﹤0.01% 1321
2024
Q1 		$99.5K Buy
+19,822
New +$111K ﹤0.01% 1345

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Assenagon Asset Management's SCPH Position: Q2 2025 in Review

Assenagon Asset Management sold out of scPharmaceuticals (SCPH) in Q2 2025, closing a stake of 12,430 shares — an estimated $32.7K sold.

Assenagon Asset Management first reported a position in SCPH in Q1 2024 and held it in 3 quarters. The position peaked at $316K in Q2 2024. 97 funds tracked by Wall St. Rank hold SCPH as of Q2 2025.

  • Assenagon Asset Management reported no remaining scPharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 12,430 scPharmaceuticals shares in Q2 2025, an estimated $32.7K.
  • Assenagon Asset Management first reported a position in scPharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Assenagon Asset Management's scPharmaceuticals position peaked at $316K in Q2 2024.
  • 97 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2025.

Based on Assenagon Asset Management's 13F filing for Q2 2025, filed 11 Jul 2025.